Veritas In Silico (TYO:130A) has launched its first in-house drug project targeting acute kidney injury after cardiovascular surgery, using an mRNA-targeted nucleic acid drug, according to a Monday filing on the Tokyo Stock Exchange.
The treatment, described as first-in-class, targets high-risk patients aged 65 and older in Japan, with peak domestic sales estimated at 15 billion yen.
Development is estimated within eight to 10 years. The drug will be developed using Veritas' ibVIS platform. The company may commercialize the treatment independently or through licensing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.